CENCORA Trademark

Trademark Overview


On Tuesday, December 26, 2023, a trademark application was filed for CENCORA with the United States Patent and Trademark Office. The USPTO has given the CENCORA trademark a serial number of 98330235. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, April 22, 2025. This trademark is owned by Cencora, Inc.. The CENCORA trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific and technological services, namely, research and design in the field of new product design and scientific research in the field of pharmacovigilance, clinical data review, chemistry data evaluation; Scientific research and laboratory research, all in the field of pharmaceuticals, medicines and medical products; industrial analysis and research services, namely, laboratory research services relating to pharmaceuticals, pharmaceutical research services, and research and development of new products for others; consulting services for others in the field of design, planning, and implementation project management in the field of pharmaceuticals, medicines and medical products; pharmaceutical product evaluation; consultancy pertaining to pharmacology; consultancy relating to research and development in the field of therapeutics; consultancy relating to laboratory testing of materials; pharmaceutical products development; testing of pharmaceuticals; provision of information and dat...
cencora

General Information


Serial Number98330235
Word MarkCENCORA
Filing DateTuesday, December 26, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, April 22, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, February 25, 2025

Trademark Statements


Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesScientific and technological services, namely, research and design in the field of new product design and scientific research in the field of pharmacovigilance, clinical data review, chemistry data evaluation; Scientific research and laboratory research, all in the field of pharmaceuticals, medicines and medical products; industrial analysis and research services, namely, laboratory research services relating to pharmaceuticals, pharmaceutical research services, and research and development of new products for others; consulting services for others in the field of design, planning, and implementation project management in the field of pharmaceuticals, medicines and medical products; pharmaceutical product evaluation; consultancy pertaining to pharmacology; consultancy relating to research and development in the field of therapeutics; consultancy relating to laboratory testing of materials; pharmaceutical products development; testing of pharmaceuticals; provision of information and data relating to medical and veterinary research and development; inspection of pharmaceuticals; information technology services for the pharmaceutical and healthcare industries, namely, information technology consulting services relating to computer network design, computer software design, information technology architecture and infrastructure, installation, maintenance and repair of computer software; quality control testing for others; materials testing and evaluation; product safety testing; consulting services for others in the field of design, planning, and implementation project management of clinical trials; providing medical and scientific research information in the fields of pharmaceuticals, drug safety, clinical research, clinical testing and clinical trials; Scientific and technological services, namely, research and design in the field of pharmaceutical development, medical devices, and biopharmaceuticals; scientific, technological, medical and pharmaceutical research and development services; industrial analysis and research services in the field of pharmaceuticals, medical devices, and biopharmaceuticals; research and development of new products for others; pharmaceutical drug development services; research and development of pharmaceutical preparations; scientific, technological, medical research and pharmaceutical research services and analysis services for scientific and technological purposes; biological research; clinical research, namely, scientific research in the nature of conducting clinical trials for others; providing medical research and scientific research information; provision of scientific information in the nature of scientific surveys; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; scientific research in the fields of pharmaceuticals, vaccines, medicine, biologics, biotherapeutics, biosimilars, therapeutics; development of a web application software for entering and evaluating informative texts for pharmaceuticals and medical products, in particular instructions for use, package inserts, specialist information and for the provision of various documents; database services, namely, electronic storage of data in computer databases; conversion of data or documents from physical to electronic media; testing, inspection or research of pharmaceuticals and medicines; design, engineering, research, development and testing services in the field of pharmaceuticals, medical devices, and biopharmaceuticals; research in the field of gene therapy; consultancy relating to quality assurance services, namely, quality assurance, quality control, quality evaluation and analysis in the field of pharmaceuticals, pharmaceutical manufacturing, medical devices, and biopharmaceuticals; research services relating to scientific work; preparation of scientific research analyses and evaluations relating to pharmaceuticals, medical devices, and biopharmaceuticals; development of pharmaceutical preparations and medicines; scientific investigations for medical purposes; conducting early evaluations in the field of new pharmaceuticals; medical research laboratory services; computer services, namely, on-site management of information technology systems for the pharmaceutical and healthcare industries; scientific evaluation of the drugs of others to determine drug efficacy; research and development services for assessing the efficiency of pharmaceuticals; analysis and evaluation of product design for others; analysis and evaluation of product development for others; quality control and evaluation of goods of others to determine conformity with certification standards; quality testing of products for certification purposes; consulting and advice on drug safety and monitoring for product research and development purposes; consultancy services for the development and approval process of biological samples or chemical samples for therapeutic and diagnostic purpose; consultancy services for others in the field of design, planning, implementation and project management of clinical trials, scientific pharmacovigilance research, pharmaceutical and biotechnology product development; consultancy services in the fields of biotechnology, pharmaceutical research and development, laboratory testing of materials and pharmacogenetics; research laboratory analysis service in the field of pharmaceuticals and biotechnology product development relating to the diagnosis and treatment of persons; Software as a service (SAAS) services featuring software for product development processes and regulatory compliance using artificial intelligence for supporting decision making processes; Software as a service (SAAS) services featuring software for supporting decision making processes; Software as a service (SAAS) services featuring software for collecting data related to clinical trials, drug development, and drug safety; Software as a service (SAAS) services, namely, automation software for collecting data related to clinical trials, drug development, and drug safety; providing online non-downloadable computer programs for data processing; providing online non-downloadable unified communications software for integrating communications systems and tools; providing online non-downloadable assistive software for collecting data related to clinical trials, drug development, and drug safety
Description of MarkThe mark consists of the stylized word "CENCORA".

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, December 26, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCencora, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressConshohocken, PA 19428

Party NameCencora, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressConshohocken, PA 19428

Trademark Events


Event DateEvent Description
Tuesday, December 26, 2023NEW APPLICATION ENTERED
Monday, April 8, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 28, 2024ASSIGNED TO EXAMINER
Wednesday, June 5, 2024NON-FINAL ACTION WRITTEN
Wednesday, June 5, 2024NON-FINAL ACTION E-MAILED
Wednesday, June 5, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, August 29, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, August 29, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Tuesday, December 3, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, December 3, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 4, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 3, 2024TEAS VOLUNTARY AMENDMENT RECEIVED
Tuesday, December 3, 2024PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Wednesday, January 22, 2025EXAMINERS AMENDMENT -WRITTEN
Wednesday, January 22, 2025EXAMINERS AMENDMENT E-MAILED
Wednesday, January 22, 2025NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, January 22, 2025EXAMINER'S AMENDMENT ENTERED
Monday, February 3, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 19, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 25, 2025PUBLISHED FOR OPPOSITION
Tuesday, February 25, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 22, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, October 20, 2025TEAS STATEMENT OF USE RECEIVED